NVSEF News and Press, Novartis Ag Basel Akt From 05/12/23

2023-05-12 09:15:18 ET Allakos ( NASDAQ: ALLK ) rose ~8% pre-market Friday after Jefferies upgraded the immunology-focused biotech to Buy from Hold, citing an attractive risk-reward setup ahead of a Phase 2 readout for its lead candidate lirentelimab. San Carlos, California-...

2023-05-10 07:05:51 ET Summary Since publishing the last article on PTC Therapeutics, the company's share price has risen 31.28%, outperforming the iShares Biotechnology ETF and the S&P 500. Overall, risdiplam is the company's third-highest-grossing medicine, with sales of CHF...

2023-05-01 16:51:05 ET Summary The May 2022 total return portfolio for 1-year is up +17.09%, and the May 2021 2-year portfolio is up 21.33%, not adjusted for greater than 2%+ dividends. The first May 2020 portfolio had +66.98% 2-year returns. 40 portfolios have been formed sin...

2023-04-28 13:00:00 ET Summary I will introduce you to 10 companies that provide investors with a relatively high Dividend Yield and which I consider attractive to invest in. On Average, the selected companies have a Dividend Yield [TTM] of 5.43%. Moreover, they have shown an Aver...

2023-04-26 13:09:44 ET Summary Novartis delivered very strong Q1 results. Sandoz spin-off is advancing, but there were no major details. The company raised its FY outlook. Despite that EPS growth is likely limited and Novartis valuations look full. Novartis ( NVS ...

2023-04-25 10:47:07 ET Novartis AG (NVS) Q1 2023 Earnings Conference Call April 25, 2023 08:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference...

2023-04-25 08:40:12 ET Summary Novartis reported strong Q1 2023 results, beating the analyst EPS and revenue consensus. Both innovative products and the Sandoz business unit performed well. Novartis increased the full-year revenue and earnings guidance after the strong perform...

2023-04-25 08:21:25 ET The following slide deck was published by Novartis AG in conjunction with their 2023 Q1 earnings call. For further details see: Novartis AG 2023 Q1 - Results - Earnings Call Presentation

2023-04-25 08:00:00 ET Summary Phathom Pharmaceuticals, Inc. received a pair of CRLs that look fairly resolvable. If resolved, Phathom Pharmaceuticals will have vonoprazan launch in two indications, one very large, in Q4. They should have enough cash and loans to survive until...

2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...